Skip to content
Screener

Revvity RVTY Diagnostics — Segment Selling, general and administrative expenses

Similar metrics at other companies

Opko Health logo
OPKDiagnostics — Selling General And Administrative Expense
$26.57M-20.4%
Thermo Fisher Scientific logo
TMOSpecialty Diagnostics — Selling, general and administrative expenses
$177M+3.5%
Abbott logo
ABTDiagnostic Products — Selling, general, and administrative
$793M+87.5%
Lear Corporation logo
LEASeating — Selling, general and administrative expenses
$97.9M+14.5%
Knife River logo
KNFCentral — Selling, general and administrative expenses
$23.27M+26.0%
TEC
TECHDiagnostics And Spatial Biology — Selling General And Administrative Expense
$27.62M-17.4%

Other financials

Income statement

See full
Revenue$711.1M+7.0%
Gross profit$387.7M+3.2%
Operating income$75.9M+5.1%
Net income$40.7M-3.6%
EPS (diluted)$0.36+2.9%

Balance sheet

See full
Cash & equivalents$861.5M-24.3%
Total debt$3.9B+17.8%
Total equity$7.2B-5.9%
Total assets$12.0B-2.9%

Cash flow

See full
Operating cash flow$115.2M-10.1%
CapEx$19.8M+23.7%
Free cash flow$95.5M-14.9%

Valuation

See full
Market cap$12.83B+28.7%
Enterprise value$15.91B+28.6%
P/E53.5×+18.6×
P/S4.4×+0.9×

Profitability

See full
Gross margin48.5%
Operating margin12.4%-1.1pp
Net margin8.3%-2.1pp
FCF margin17%-1.9pp

Returns & leverage

See full
Return on equity3.2%-0.5pp
Debt / equity0.5×+0.1×
Current ratio1.7×-1.9×

Where this comes from

Reported directly by Revvity in its filing.

Tagged under the XBRL concept revv:SegmentSellingGeneralAndAdministrativeExpenses.

The source filing: Revvity’s 10-Q, filed May 12, 2026.

Filed
May 12, 2026, 4:07 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0000031791-26-000019
Line itemApril 5, 2026 / Life SciencesApril 5, 2026 / DiagnosticsApril 5, 2026 / TotalMarch 30, 2025 / Life SciencesMarch 30, 2025 / DiagnosticsMarch 30, 2025 / Total
Segment revenue$361,845$349,273$711,118$340,395$324,367$664,762
Segment cost of revenue131,574156,753119,321135,190
Segment selling, general and administrative expenses94,66890,19287,09489,891
Segment research and development expenses31,62426,20628,26925,271
Segment operating income$103,979$76,122180,101$105,711$74,015179,726
Corporate expenses(12,247)(9,815)
Amortization of intangible assets(85,081)(82,700)
Purchase accounting adjustments(141)177

Item 1.Unaudited Financial Statements

FAQ

What is Revvity's diagnostics — segment selling, general and administrative expenses?
Revvity (RVTY) reported diagnostics — segment selling, general and administrative expenses of $90.19M in Q1 2026.
How has Revvity's diagnostics — segment selling, general and administrative expenses changed year-over-year?
Revvity's diagnostics — segment selling, general and administrative expenses increased by 0.3% year-over-year, from $89.89M to $90.19M.
What is the long-term trend for Revvity's diagnostics — segment selling, general and administrative expenses?
Over 3 years (2022 to 2025), Revvity's diagnostics — segment selling, general and administrative expenses has grown at a -4.9% compound annual growth rate (CAGR), from $399.55M to $343.43M.
What does diagnostics — segment selling, general and administrative expenses mean?
Covers the indirect costs of operating the diagnostics segment, including sales force compensation, marketing, legal, and administrative overhead. These expenses support the infrastructure required to sell and manage the segment's business.

Ask your AI about Revvity's diagnostics — segment selling, general and administrative expenses.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude